Article

iX Biopharma Ltd has secured approximately $41 million from the U.S. government to develop its Wafermine therapy for pain management. The funding, awarded by the Defense Health Agency, aims to enhance the therapy's commercial viability and prepare it for potential battlefield use. The three-year program seeks Emergency Use Authorization from the FDA and supports Phase 3 development for a New Drug Application.